Eli Lilly and Company’s LLY shares dipped almost 5% on Monday after rival Novo Nordisk NVO announced disappointing data from ...

Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh® (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn ...

“This is a significant milestone for our efforts to advance medicines for IBD using insights from our proprietary 3D human tiss Today Eli Lilly and Company (NYSE: LLY) announced the launch of 7.5 mg ...

Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's disease, extending its use beyond ulcerative colitis (UC) for the first time.

In the trials, omalizumab and multi-allergen oral immunotherapy showed alike efficacy in protecting against food allergies, ...

Ozempic and other GLP-1 drugs like it have become so pervasive in the zeitgeist that it’s likely even your most social ...

This article delves into the three approved assets in this class – AbbVie’s Skyrizi (risankizumab), Eli Lilly’s Omvoh (mirikizumab), and J&J’s Tremfya (guselkumab) – and explores how ...

Read on to learn about magnesium's benefits, types and dosage suggestions so you can decide if it's worth trying for your sleep needs. Magnesium is an essential mineral in the body that plays a ...

A month after a stampede at New Delhi railway station that killed 18, the government revealed 49,000 general tickets were sold on February 15, significantly higher than the average. This spike led ...